Delaware | 000-50789 | 33-0145723 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
DIGIRAD CORPORATION | |||
By: | /s/ Jeffry R. Keyes | ||
Jeffry R. Keyes Chief Financial Officer |
Exhibit No. | Description | |
99.1 | Press Release dated May 6, 2013, announcing financial results for the three months ended March 31, 2013. | |
99.2 | Information Related to the use of Non-GAAP Financial Measures. |
• | A significant restructuring, primarily of the Diagnostic Imaging camera operation to reduce costs by $3 million to $4 million, on an annual basis. |
• | A go-forward focus on maximizing and growing cash flow from its DIS services business. This strategy will include executing on financially disciplined acquisitions that align to and expand cash flow from the DIS operations. The diagnostic imaging business will emphasize a streamlined camera selling effort and efficiency in generating cash flow from the service and maintenance business associated with its installed base of cameras. |
• | The aggressive return of cash to shareholders via an increased stock repurchase program, for which the Board ultimately increased the stock repurchase program from its existing $4 million program ($2 million availability) to a $12 million program ($10 million availability). |
• | Total revenue for the first quarter of 2013 was $11.5 million, compared to $13.0 million for the same period in the prior year. DIS revenue for the first quarter of 2013 was $8.9 million, compared to $9.3 million for the same period of the prior year, which included some pricing pressures experience during the 2013 first quarter. Diagnostic Imaging revenue for the first quarter of 2013 was $2.6 million, compared to $3.7 million for the same period of the prior year, reflecting a disruption as the Company deployed its restructuring plan. |
• | Gross profit for the first quarter of 2013 was $2.8 million, or 24 percent of revenue, compared to $3.7 million, or 28 percent of revenue in the prior year quarter. |
• | Net loss for the first quarter of 2013 was $2.4 million, or $0.13 loss per share, compared to a net loss of $1.3 million, or $0.07 loss per share, in the same period of the prior year. Adjusted net loss for the 2013 first quarter, excluding the $1.0 million in expenses incurred for nonrecurring items related to restructuring activities, was $1.4 million or $0.07 loss per share on an adjusted basis. |
• | Operating expenses for the first quarter of 2013 was $5.2 million, compared to $5.0 million in the same period in the prior year. Adjusted operating expenses for the first quarter of 2013 was $4.2 million, compared to the $5.0 million in the same period of the prior year, which reflects the beginning of the restructuring expense reductions since the February 28, 2013 restructuring announcement. |
• | Cash, cash equivalents and available-for-sale securities totaled $25.8 million as of March 31, 2013. Cash, cash equivalents and available-for-sale securities totaled $27.2 million as of December 31, 2012. |
Investor Contact: Matt Clawson Allen & Caron 949-474-4300 matt@allencaron.com | Company Contact: Jeffry Keyes, CFO 858-726-1600 ir@digirad.com |
Three Months Ended | |||||||
(in thousands, except per share data) | March 31, | ||||||
2013 | 2012 | ||||||
Revenues: | |||||||
DIS | $ | 8,939 | $ | 9,289 | |||
Diagnostic Imaging | 2,607 | 3,680 | |||||
Total revenues | 11,546 | 12,969 | |||||
Cost of revenues: | |||||||
DIS | 6,825 | 6,976 | |||||
Diagnostic Imaging | 1,904 | 2,321 | |||||
Total cost of revenues | 8,729 | 9,297 | |||||
Gross profit | 2,817 | 3,672 | |||||
Operating expenses: | |||||||
Research and development | 818 | 897 | |||||
Marketing and sales | 1,236 | 1,715 | |||||
General and administrative | 2,102 | 2,265 | |||||
Amortization of intangible assets | 66 | 77 | |||||
Restructuring charges | 1,004 | — | |||||
Total operating expenses | 5,226 | 4,954 | |||||
Loss from operations | (2,409 | ) | (1,282 | ) | |||
Other income (expense): | |||||||
Interest income | 22 | 26 | |||||
Other expense | (32 | ) | (12 | ) | |||
Total other income (expense) | (10 | ) | 14 | ||||
Net loss | $ | (2,419 | ) | $ | (1,268 | ) | |
Net loss per share: Basic and diluted | $ | (0.13 | ) | $ | (0.07 | ) | |
Shares used in per share computations: | |||||||
Weighted average shares outstanding: Basic and diluted | 19,322 | 19,242 |
(in thousands, except per share data) | Three Months Ended March 31, 2013 | ||||||||||
Nonrecurring | |||||||||||
GAAP | Items 1 | Adjusted 2 | |||||||||
Revenues: | |||||||||||
DIS | $ | 8,939 | $ | — | $ | 8,939 | |||||
Diagnostic Imaging | 2,607 | — | 2,607 | ||||||||
Total revenues | 11,546 | — | 11,546 | ||||||||
Cost of revenues: | |||||||||||
DIS | 6,825 | — | 6,825 | ||||||||
Diagnostic Imaging | 1,904 | — | 1,904 | ||||||||
Total cost of revenues | 8,729 | — | 8,729 | ||||||||
Gross profit | 2,817 | — | 2,817 | ||||||||
Operating expenses: | |||||||||||
Research and development | 818 | — | 818 | ||||||||
Marketing and sales | 1,236 | — | 1,236 | ||||||||
General and administrative | 2,102 | — | 2,102 | ||||||||
Amortization of intangible assets | 66 | — | 66 | ||||||||
Restructuring charges | 1,004 | (1,004 | ) | — | |||||||
Total operating expenses | 5,226 | (1,004 | ) | 4,222 | |||||||
Loss from operations | (2,409 | ) | 1,004 | (1,405 | ) | ||||||
Other income (expense): | |||||||||||
Interest income | 22 | — | 22 | ||||||||
Other expense | (32 | ) | — | (32 | ) | ||||||
Total other income (expense) | (10 | ) | — | (10 | ) | ||||||
Net loss | $ | (2,419 | ) | $ | 1,004 | $ | (1,415 | ) | |||
Net loss per share: Basic and diluted 3 | $ | (0.13 | ) | $ | 0.05 | $ | (0.07 | ) | |||
Shares used in per share computations: | |||||||||||
Weighted average shares outstanding: Basic and diluted | 19,322 | 19,322 | 19,322 |
(in thousands, except per share data) | Three Months Ended March 31, 2012 | ||||||||||
Nonrecurring | |||||||||||
GAAP | Items 1 | Adjusted 2 | |||||||||
Revenues: | |||||||||||
DIS | $ | 9,289 | $ | — | $ | 9,289 | |||||
Diagnostic Imaging | 3,680 | — | 3,680 | ||||||||
Total revenues | 12,969 | — | 12,969 | ||||||||
Cost of revenues: | |||||||||||
DIS | 6,976 | — | 6,976 | ||||||||
Diagnostic Imaging | 2,321 | — | 2,321 | ||||||||
Total cost of revenues | 9,297 | — | 9,297 | ||||||||
Gross profit | 3,672 | — | 3,672 | ||||||||
Operating expenses: | |||||||||||
Research and development | 897 | — | 897 | ||||||||
Marketing and sales | 1,715 | — | 1,715 | ||||||||
General and administrative | 2,265 | — | 2,265 | ||||||||
Amortization of intangible assets | 77 | — | 77 | ||||||||
Total operating expenses | 4,954 | — | 4,954 | ||||||||
Loss from operations | (1,282 | ) | — | (1,282 | ) | ||||||
Other income (expense): | |||||||||||
Interest income | 26 | — | 26 | ||||||||
Other expense | (12 | ) | — | (12 | ) | ||||||
Total other income (expense) | 14 | — | 14 | ||||||||
Net loss | $ | (1,268 | ) | $ | — | $ | (1,268 | ) | |||
Net loss per share: Basic and diluted | $ | (0.07 | ) | $ | — | $ | (0.07 | ) | |||
Shares used in per share computations: | |||||||||||
Weighted average shares outstanding: Basic and diluted | 19,242 | 19,242 | 19,242 |
Three Months Ended March 31, 2013 | |||||||||||
Nonrecurring | |||||||||||
(in thousands) | GAAP | Items 1 | Adjusted 2 | ||||||||
DIS | |||||||||||
Revenue | $ | 8,939 | $ | — | $ | 8,939 | |||||
Gross Profit | 2,114 | — | 2,114 | ||||||||
Operating loss | (144 | ) | — | (144 | ) | ||||||
Diagnostic Imaging | |||||||||||
Revenue | $ | 2,607 | $ | — | $ | 2,607 | |||||
Gross Profit | 703 | — | 703 | ||||||||
Operating loss | (2,265 | ) | 1,004 | (1,261 | ) | ||||||
Three Months Ended March 31, 2012 | |||||||||||
Nonrecurring | |||||||||||
(in thousands) | GAAP | Items 3 | Adjusted 2 | ||||||||
DIS | |||||||||||
Revenue | $ | 9,289 | $ | — | $ | 9,289 | |||||
Gross Profit | 2,313 | — | 2,313 | ||||||||
Operating loss | (168 | ) | — | (168 | ) | ||||||
Diagnostic Imaging | |||||||||||
Revenue | $ | 3,680 | $ | — | $ | 3,680 | |||||
Gross Profit | 1,359 | — | 1,359 | ||||||||
Operating loss | (1,114 | ) | — | (1,114 | ) |